C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense.

Apolipoprotein L-I (apoL1) is a human-specific serum protein that kills Trypanosoma brucei through ionic pore formation in endosomal membranes of the parasite. The T. brucei subspecies rhodesiense and gambiense resist this lytic activity and can infect humans, causing sleeping sickness.

Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes.

Apolipoprotein L-I is the trypanolytic factor of human serum. Here we show that this protein contains a membrane pore-forming domain functionally similar to that of bacterial colicins, flanked by a membrane-addressing domain. In lipid bilayer membranes, apolipoprotein L-I formed anion channels.

Trypanosoma brucei: growth differences in different mammalian sera are not due to the species-specificity of transferrin.

The heterodimeric transferrin receptors of Trypanosoma brucei (Tf-Rs) are encoded by two genes termed ESAG7 and ESAG6. These genes belong to polycistronic transcription units contained in the multiple expression sites for the variant surface glycoprotein (VSG ESs), only one of which is active at a time. Each VSG ES carries a different copy of these genes, leading to alternative expression of Tf-Rs with quite distinct binding affinities for transferrins from various mammals.

Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Human sleeping sickness in east Africa is caused by the parasite Trypanosoma brucei rhodesiense. The basis of this pathology is the resistance of these parasites to lysis by normal human serum (NHS). Resistance to NHS is conferred by a gene that encodes a truncated form of the variant surface glycoprotein termed serum resistance associated protein (SRA).